Associated Papers
An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H et al.
Ebiomedicine, 2019
31668570 (PubMed )
Supplement: mmc3.xlsx › Sheet1
DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease.
Quesada AE et al.
American Journal of Hematology, 2019
Select a paper to view details